Patients with eating disorders should be carefully assessed before, during and after treatment with GLP-1 receptor agonists, according to clinical psychologist Leslie Heinberg, PhD, MA, of Cleveland Clinic, who told Psychiatric Times that the drugs’ appetite-suppressing effects may reinforce dietary restriction and the drive for thinness. The expert guidance, published by Psychiatric Times on October 30, 2026, arrives as GLP-1 prescribing expands rapidly across weight-loss clinics, telehealth platforms and peptide therapy providers in the United States. For the peptide therapy industry, the warning reframes eating-disorder screening as a prescribing prerequisite rather than an optional add-on.
The nut graf: GLP-1 peptides such as semaglutide and tirzepatide are the commercial engine of the weight-loss clinic boom, and any signal that these molecules may worsen or mask disordered eating goes directly to how clinics qualify patients, document records and structure follow-up. Heinberg’s position that GLP-1s are contraindicated in patients with eating disorders, combined with her call for specialist referral when an eating disorder is suspected, sets a higher operational bar for clinics that currently rely on brief intake questionnaires.
What happened: Heinberg’s guidance on GLP-1s and eating disorders
In the Psychiatric Times interview, Heinberg described how anorexia nervosa and bulimia nervosa are characterized by a pathological pursuit of thinness, often pursued through severe dietary restriction and compensatory behaviors such as purging by vomiting, laxatives or excessive exercise. Patients with these conditions may seek obesity medications such as GLP-1s precisely because of that pursuit, and pervasive media and social media coverage of dramatic weight loss may make pursuing prescriptions even more compelling, she said.
Heinberg also addressed binge eating disorder, where patients may seek GLP-1s for symptom reduction. Preliminary studies in patients with both obesity and binge eating disorder found fewer binge eating episodes, lower body weight and less preoccupation with food, according to her account of the literature. She cautioned, however, that long-term impact on binge eating disorder has not been studied and that outcomes after GLP-1 discontinuation have not been evaluated.
Mechanistically, Heinberg said GLP-1s facilitate weight loss by delaying gastric emptying, which produces a greater sense of fullness or satiety, and that evidence suggests the drugs act on the brain’s reward centers, reducing appetite and food-related reward — effects that may relate to the subjective experience of reduced “food noise.” For patients attempting to restrict intake, she said, these medications may reinforce the ability to restrict, and the resulting weight loss may reinforce the drive for thinness.
Key numbers and evidence status: what is established and what is not
The evidence base behind the warning is uneven, and the distinction matters for clinicians who must decide how aggressively to screen. The binge eating disorder findings are preliminary and short-term; the long-term and post-discontinuation questions are explicitly unstudied. Heinberg’s contraindication statement is a clinical position rather than a regulatory citation in the article, and no well-controlled randomized trial of GLP-1s in eating disorder populations is cited as completed.
| Element | What the source states | Evidence status |
|---|---|---|
| Binge eating disorder outcomes | Fewer binge episodes, lower weight, less food preoccupation in preliminary studies of patients with obesity plus binge eating disorder | Preliminary, short-term; long-term effects unstudied |
| Post-discontinuation outcomes | Not evaluated | Evidence gap |
| Restriction reinforcement | GLP-1s may reinforce the ability to restrict and the drive for thinness | Expert hypothesis, hedged with “may” |
| Contraindication | GLP-1s are contraindicated in patients with eating disorders | Heinberg’s clinical position; no regulatory citation in the article |
| Randomized trials | Well-controlled randomized trials in eating disorders are needed | Identified as a major evidence gap |
Two quantified anchors frame the clinical concern: the preliminary binge eating disorder studies reported reductions in binge eating episodes and body weight, while the durability of those effects beyond the short term remains unmeasured. Heinberg’s example of a steadily declining weight goal — wanting to lose another 15 lbs and then another upon reaching the goal — illustrates the behavioral pattern clinicians are being asked to watch for.
Why it matters for peptide therapy clinics and telehealth
For clinic operators, the practical consequence is a documentation and workflow problem. Heinberg recommended that providers consider a brief eating disorder screen and a review of the patient’s record before prescribing, looking for recent rapid weight loss, electrolyte imbalances or past eating disorder diagnoses, with referral to eating disorder specialists warranted when an eating disorder is suspected. She also suggested asking about all medications and supplements, not just GLP-1s, including those from other providers, online providers or ordered off the internet, because a broader framing can reduce defensiveness and feelings of being judged.
During treatment, she flagged concerning signs: weight loss much faster than expected, purging, restriction or excessive exercise, increasing preoccupation with food and weight, and a steadily declining weight goal. For patients with an eating disorder who are already using an unregulated GLP-1, Heinberg recommended specialized multidisciplinary care, education on the potential risk, and a clear statement that these medications are contraindicated for them.
This is where supply-chain and sourcing practices intersect with clinical risk. Clinics that source GLP-1 products outside approved channels inherit a patient-safety problem they cannot document away, and the industry’s sourcing directories — including peptidescm and PeptideDDP — are increasingly used by operators to trace where a given vial or pen originated before it reaches a patient. Heinberg’s recommendation to assess patients before initiation, during treatment and after discontinuation implies that clinics need longitudinal records, not one-time intake forms.
She also recommended that GLP-1 prescriptions for weight loss be augmented with healthy eating guidance, protein recommendations, calorie goals that are not overly restrictive, and weight-bearing exercise to avoid lean muscle mass loss, adding that difficulty following these recommendations may indicate that additional eating disorder screening is necessary.
Research and market context: the evidence gap behind the prescribing boom
The article cites two background references: a 2024 paper in the International Journal of Eating Disorders (volume 57, issue 2, pages 286–293) on the use of GLP-1 receptor agonists in eating disorder populations, and a 2025 systematic review and meta-analysis in Eating and Weight Disorders (volume 30, issue 1, article 10) on GLP-1 agonists in the treatment of eating disorders. Heinberg’s stated research priorities include well-controlled randomized trials of GLP-1s for binge eating disorder, studies identifying which patients may derive the greatest benefit, and evaluation of the incidence of de novo eating disorder symptoms, recurrence in those with a history, and the frequency of sub-threshold disordered eating symptoms.
For the research peptide and API supply side, the warning does not change the molecules themselves, but it does change the questions buyers ask. Clinics evaluating a supplier increasingly want batch-level documentation, identity and purity data, and traceability that can support a patient record if an adverse event is later reviewed. A certificate of analysis reports specified analytical results for a material or batch; it does not independently establish clinical safety, efficacy, sterility for a particular use, regulatory approval, or suitability for administration to humans. That distinction is central to how clinics should read supplier claims.
Industry observers note that the eating disorder question is likely to become a differentiator among peptide therapy clinics: operators with structured screening, specialist referral pathways and documented follow-up may be better positioned as scrutiny of GLP-1 prescribing intensifies, while those relying on minimal intake screening may face higher clinical and reputational exposure. This suggests that the commercial value of a screening protocol lies less in marketing than in risk management.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What comes next: monitoring, documentation and the trial agenda
The near-term watch items are concrete. First, whether clinics adopt Heinberg’s brief screen and record review as a standard pre-prescription step, and whether telehealth platforms build those questions into intake flows. Second, whether payers or regulators begin asking for evidence of eating disorder screening in GLP-1 prescribing records. Third, whether the randomized trial agenda she outlined — binge eating disorder efficacy, patient selection, de novo symptoms, recurrence and sub-threshold symptoms — begins to produce data that clarifies the risk-benefit balance.
Until then, the evidence does not establish that GLP-1s cause eating disorders, nor that they reliably treat binge eating disorder beyond the short term. What it does establish is a plausible mechanism by which appetite suppression and weight loss could reinforce restriction in vulnerable patients, and a clear clinical recommendation that those patients be identified and referred. For peptide therapy clinics, the operational takeaway is that screening, documentation and specialist referral are now part of the standard of care conversation around GLP-1 peptides — and that the quality of the product record behind each prescription will matter if that conversation turns into a review.
Comments